Ensysce Biosciences, Inc (ENSC): Price and Financial Metrics


Ensysce Biosciences, Inc (ENSC): $0.53

0.01 (+2.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENSC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENSC Stock Price Chart Interactive Chart >

Price chart for ENSC

ENSC Price/Volume Stats

Current price $0.53 52-week high $17.12
Prev. close $0.52 52-week low $0.46
Day low $0.50 Volume 526,100
Day high $0.54 Avg. volume 1,032,420
50-day MA $0.96 Dividend yield N/A
200-day MA $2.17 Market Cap 18.32M

Ensysce Biosciences, Inc (ENSC) Company Bio


Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.


ENSC Latest News Stream


Event/Time News Detail
Loading, please wait...

ENSC Latest Social Stream


Loading social stream, please wait...

View Full ENSC Social Stream

Latest ENSC News From Around the Web

Below are the latest news stories about Ensysce Biosciences Inc that investors may wish to consider to help them evaluate ENSC as an investment opportunity.

Ensysce Biosciences Announces Participation in the 34th Annual Roth Conference

SAN DIEGO, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced management’s participation in the 34th Annual Roth Conference being held March 13-15, 2022 at the Ritz Carlton, Laguna Niguel in Dana Point, C

Yahoo | February 23, 2022

Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

SAN DIEGO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance with a focus on reducing abuse and overdose while providing relief for those with severe pain, today announced that Lee Rauch has been appointed to the Company’s board of directors. Ms. Rauch, an experienced Chief Executive Officer and Strategy Advisor,

Yahoo | February 8, 2022

Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program

SAN DIEGO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting against abuse and overdose, announced today the Company has engaged international investor relations specialists MZ Group (“MZ”) to lead a comprehensive strategic investor relations and financial communications program acr

Yahoo | January 31, 2022

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

SAN DIEGO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with two novel technology platforms designed to provide relief for those suffering with severe pain while protecting against abuse and overdose, today announced the results of the special meeting of stockholders held January 26, 2022. This meeting was held virtually, and the following resolutions were submitted and adopted by the stockho

Yahoo | January 27, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investor!

William White on InvestorPlace | January 19, 2022

Read More 'ENSC' Stories Here

ENSC Price Returns

1-mo -51.82%
3-mo -52.68%
6-mo -66.46%
1-year -96.17%
3-year N/A
5-year N/A
YTD -88.72%
2021 -62.20%
2020 19.33%
2019 6.11%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6143 seconds.